Article
Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk.
Cells - 27 Jul 2023
Gómez-Vecino Aurora, Corchado-Cobos Roberto, Blanco-Gómez Adrián, García-Sancha Natalia, Castillo-Lluva Sonia, Martín-García Ana, Mendiburu-Eliçabe Marina, Prieto Carlos, Ruiz-Pinto Sara, Pita Guillermo, Velasco-Ruiz Alejandro, Patino-Alonso Carmen, Galindo-Villardón Purificación, Vera-Pedrosa María Linarejos, Jalife José, Mao Jian-Hua, Macías de Plasencia Guillermo, Castellanos-Martín Andrés, Sáez-Freire María Del Mar, Fraile-Martín Susana, Rodrigues-Teixeira Telmo, García-Macías Carmen, Galvis-Jiménez Julie Milena, García-Sánchez Asunción, Isidoro-García María, Fuentes Manuel, García-Cenador María Begoña, García-Criado Francisco Javier, García-Hernández Juan Luis, Hernández-García María Ángeles, Cruz-Hernández Juan Jesús, Rodríguez-Sánchez César Augusto, García-Sancho Alejandro Martín, Pérez-López Estefanía, Pérez-Martínez Antonio, Gutiérrez-Larraya Federico, Cartón Antonio J, García-Sáenz José Ángel, Patiño-García Ana, Martín Miguel, Alonso-Gordoa Teresa, Vulsteke Christof, Croes Lieselot, Hatse Sigrid, Van Brussel Thomas, Lambrechts Diether, Wildiers Hans, Chang Hang, Holgado-Madruga Marina, González-Neira Anna, Sánchez Pedro L, Pérez Losada Jesús
Abstract excerpt
Cardiotoxicity due to anthracyclines (CDA) affects cancer patients, but we cannot predict who may suffer from this complication. CDA is a complex trait with a polygenic component that is mainly unidentified. We propose that levels of intermediate molecular phenotypes (IMPs) in the myocardium associated with histopathological damage could explain CDA susceptibility, so variants of genes encoding these IMPs could...
Read the complete abstract on PubMed